RESMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.2 USD | +2.16% |
|
-0.33% | +7.11% |
| Apr. 17 | Wall St set for higher open on megacaps boost; earnings, Fed comments on tap | RE |
| Apr. 01 | Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 27.83 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +7.11% | 27.06B | B+ | ||
| +8.35% | 219B | B | ||
| +9.41% | 187B | B- | ||
| +11.75% | 134B | B- | ||
| +19.34% | 101B | A- | ||
| +0.68% | 62.27B | A- | ||
| +15.08% | 52.82B | B+ | ||
| -2.10% | 47.49B | B+ | ||
| +0.10% | 40.79B | A | ||
| +11.50% | 39.35B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RMD Stock
- Ratings ResMed, Inc.
